These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28413925)

  • 1. Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial.
    Frick G; Yan B; Adler LA
    J Atten Disord; 2020 Feb; 24(3):402-413. PubMed ID: 28413925
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 4. A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD.
    Adler LA; Frick G; Yan B
    J Atten Disord; 2020 Feb; 24(3):434-446. PubMed ID: 28412886
    [No Abstract]   [Full Text] [Related]  

  • 5. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder.
    Surman CBH; Robertson B; Chen J; Cortese S
    CNS Drugs; 2019 Jul; 33(7):695-706. PubMed ID: 31228031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.
    Wigal T; Childress A; Frick G; Yan B; Wigal S; Madhoo M
    Postgrad Med; 2018 Jan; 130(1):111-121. PubMed ID: 29087231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
    Wigal T; Brams M; Frick G; Yan B; Madhoo M
    Postgrad Med; 2018 Jun; 130(5):481-493. PubMed ID: 29809075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study.
    Spencer TJ; Adler LA; Weisler RH; Youcha SH
    J Clin Psychiatry; 2008 Sep; 69(9):1437-48. PubMed ID: 19012813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
    Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
    Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study.
    Spencer TJ; Landgraf JM; Adler LA; Weisler RH; Anderson CS; Youcha SH
    J Clin Psychiatry; 2008 Nov; 69(11):1766-75. PubMed ID: 19026251
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Adler LA; Robertson B; Chen J; Sarkis E
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):427-438. PubMed ID: 32423239
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies.
    Brown TE; Chen J; Robertson B
    J Atten Disord; 2022 Jan; 26(2):256-266. PubMed ID: 33150816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
    Ilic K; Kugler AR; Yan B; McNamara N
    CNS Drugs; 2022 Jan; 36(1):71-81. PubMed ID: 34826114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release.
    Ermer JC; Shojaei A; Pennick M; Anderson CS; Silverberg A; Youcha SH
    Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.